Meeting
2019 ASCO Annual Meeting
ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC).
Authors
Anne-Claire Hardy-Bessard
CARIO-HPCA and Cooperative Gynecological Cancer Research Group (GINECO), Plerin, France
Anne-Claire Hardy-Bessard , Kathleen N. Moore , Mansoor Raza Mirza , Bernard Asselain , Andres Redondo , Jacobus Pfisterer , Sandro Pignata , Diane M. Provencher , David Cibula , Anna K.L. Reyners , Lubomir Bodnar , Rosalind Margaret Glasspool , Christos A. Papadimitriou , Rami Eitan , Sileny Han , Linda R. Duska , Bj Rimel , Sebastien Hazard , Jian Chen , Eric Pujade-Lauraine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT03602859
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS5600)
DOI
10.1200/JCO.2019.37.15_suppl.TPS5600
Abstract #
TPS5600
Poster Bd #
420a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC).
First Author: Anne-Claire Hardy-Bessard
Poster
2019 ASCO Annual Meeting
ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.
First Author: Ignace Vergote
Poster
2022 ASCO Annual Meeting
AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer—A multicenter, randomized, phase III trial.
First Author: Florian Heitz
Poster
2020 ASCO Virtual Scientific Program
DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC).
First Author: Shannon Neville Westin